These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 21663331

  • 1. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
    Lewis JH.
    Drug Saf; 2011 Jul 01; 34(7):545-65. PubMed ID: 21663331
    [Abstract] [Full Text] [Related]

  • 2. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
    Chang L, Tong K, Ameen V.
    Am J Gastroenterol; 2010 Apr 01; 105(4):866-75. PubMed ID: 20197759
    [Abstract] [Full Text] [Related]

  • 3. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.
    Chey WD, Cash BD.
    Expert Opin Investig Drugs; 2005 Feb 01; 14(2):185-93. PubMed ID: 15757394
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.
    Binienda A, Storr M, Fichna J, Salaga M.
    Curr Drug Targets; 2018 Feb 01; 19(15):1774-1781. PubMed ID: 29284389
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R, Nikfar S, Abdollahi M.
    Clin Ther; 2008 May 01; 30(5):884-901. PubMed ID: 18555935
    [Abstract] [Full Text] [Related]

  • 6. Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats.
    Painsipp E, Shahbazian A, Holzer P.
    Br J Pharmacol; 2009 Nov 01; 158(5):1210-26. PubMed ID: 19785647
    [Abstract] [Full Text] [Related]

  • 7. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
    Hasler WL, Schoenfeld P.
    Drug Saf; 2004 Nov 01; 27(9):619-31. PubMed ID: 15230644
    [Abstract] [Full Text] [Related]

  • 8. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F, Tonini M.
    Drugs; 2001 Nov 01; 61(3):317-32. PubMed ID: 11293643
    [Abstract] [Full Text] [Related]

  • 9. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH.
    Expert Rev Gastroenterol Hepatol; 2010 Feb 01; 4(1):13-29. PubMed ID: 20136586
    [Abstract] [Full Text] [Related]

  • 10. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
    Johanson JF.
    Neurogastroenterol Motil; 2004 Dec 01; 16(6):701-11. PubMed ID: 15601419
    [Abstract] [Full Text] [Related]

  • 11. [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
    Komoto S, Miura S.
    Nihon Rinsho; 2006 Aug 01; 64(8):1487-90. PubMed ID: 16898618
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
    Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P.
    Am J Gastroenterol; 2009 Jul 01; 104(7):1831-43; quiz 1844. PubMed ID: 19471254
    [Abstract] [Full Text] [Related]

  • 13. Alosetron and irritable bowel syndrome.
    Mayer EA, Bradesi S.
    Expert Opin Pharmacother; 2003 Nov 01; 4(11):2089-98. PubMed ID: 14596662
    [Abstract] [Full Text] [Related]

  • 14. Tegaserod-associated ischemic colitis.
    DiBaise JK.
    Pharmacotherapy; 2005 Apr 01; 25(4):620-5. PubMed ID: 15977922
    [Abstract] [Full Text] [Related]

  • 15. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.
    Lembo A, Weber HC, Farraye FA.
    Drugs; 2003 Apr 01; 63(18):1895-905. PubMed ID: 12930162
    [Abstract] [Full Text] [Related]

  • 16. Tegaserod and other serotonergic agents: what is the evidence?
    Chey WD.
    Rev Gastroenterol Disord; 2003 Apr 01; 3 Suppl 2():S35-40. PubMed ID: 12776001
    [Abstract] [Full Text] [Related]

  • 17. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
    Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M.
    Clin Gastroenterol Hepatol; 2008 May 01; 6(5):545-55. PubMed ID: 18242143
    [Abstract] [Full Text] [Related]

  • 18. Tegaserod: a serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome.
    Cole P, Rabasseda X.
    Drugs Today (Barc); 2004 Dec 01; 40(12):1013-30. PubMed ID: 15645012
    [Abstract] [Full Text] [Related]

  • 19. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.
    Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P.
    Am J Gastroenterol; 2006 May 01; 101(5):1069-79. PubMed ID: 16606352
    [Abstract] [Full Text] [Related]

  • 20. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB, Wilhelm SM.
    Pharmacotherapy; 2007 Feb 01; 27(2):267-77. PubMed ID: 17253916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.